Systemic Inflammatory Response and Sepsis Pathology

Pattern Recognition and Innate Immune Activation

• Pathogen-associated molecular patterns (PAMPs) recognition: Bacterial lipopolysaccharide (LPS), peptidoglycans, flagellin, and fungal β-glucans bind toll-like receptors (TLRs) (particularly TLR4 for gram-negative LPS) on monocytes, macrophages, dendritic cells, and endothelial cells
• Damage-associated molecular patterns (DAMPs) from necrotic tissue activate similar pathways—ATP, high-mobility group box 1 (HMGB1), heat shock proteins, and nucleic acids signal danger independent of infection
• CD14 and MD2 co-receptors facilitate LPS-TLR4 complex formation, initiating MyD88-dependent NF-κB and MAPK signaling cascades
• NLRP3 inflammasome activation occurs through two-signal mechanism: TLR priming (signal 1) followed by danger signals like ATP, nigericin, or pore-forming toxins (signal 2), resulting in caspase-1 activation
• Caspase-1 cleaves pro-IL-1β and pro-IL-18 into their active forms, amplifying inflammatory cascade

Cytokine Storm and Mediator Release

• Tumor necrosis factor-α (TNF-α) release from macrophages and monocytes initiates the cytokine cascade; correlates with mortality severity and induces endothelial expression of adhesion molecules (ICAM-1, VCAM-1, selectins)
• Interleukin-1β (IL-1β) and IL-6 amplify inflammation through hepatic acute phase protein synthesis (CRP, serum amyloid A), hypothalamic temperature setpoint elevation (fever), and further leukocyte recruitment
• Interleukin-8 (IL-8) and other C-X-C chemokines create chemotactic gradients driving neutrophil extravasation into tissues
• TNF-α, IL-1β, and IL-6 collectively increase vascular endothelial growth factor (VEGF) and reduce tight junction protein expression (occludin, claudins, ZO-1), compromising the endothelial glycocalyx (200-500 nm carbohydrate-rich layer on luminal surface)
• Complement cascade activation through classical (antibody-mediated) and alternative pathways generates C3a and C5a anaphylatoxins, which activate mast cells, increase vascular permeability, and enhance leukocyte chemotaxis
• Bradykinin generation through contact system activation (Factor XII/Hageman factor) causes vasodilation and increased capillary permeability

Coagulation Cascade Dysregulation and Thromboinflammation

• Tissue factor (TF) on monocyte and endothelial cell surfaces, upregulated by TNF-α and LPS, initiates extrinsic coagulation pathway and generates thrombin (Factor IIa)
• Thrombin-activatable fibrinolysis inhibitor (TAFI) suppresses fibrinolysis while thrombin stimulates platelet aggregation and releases platelet factor 4 (PF4) and P-selectin, creating prothrombotic state
• Protein C, protein S, and antithrombin levels decline due to consumption and reduced hepatic synthesis, further promoting thrombosis
• Tissue plasminogen activator (tPA) is inhibited by increased plasminogen activator inhibitor-1 (PAI-1), suppressing fibrinolysis—the "DIC-sepsis death spiral"
• Widespread microvascular thrombosis creates perfusion deficits with ischemic organ injury, particularly affecting kidneys, liver, lungs, and brain
• Platelet consumption and aggregation contribute to thrombocytopenia (often prognostically significant when <100,000/μL)

Endothelial Dysfunction and Vascular Leak

• Endothelial cell apoptosis occurs through TNF-α/TRAIL signaling and reactive oxygen species (ROS) generation, disrupting monolayer integrity
• VEGF dysregulation (increased production but reduced receptor signaling in early sepsis) and loss of angiopoietin-1 (Ang-1) signaling reduce VE-cadherin and adherens junction stability
• Matrix metalloproteinase (MMP-2 and MMP-9) upregulation degrades Type IV collagen and fibronectin in basement membrane, allowing leukocyte extravasation and increasing capillary permeability
• Reactive oxygen species (ROS) produced by activated neutrophils and mitochondrial dysfunction oxidize lipids, proteins, and nucleic acids—oxidative stress drives endothelial dysfunction, mitochondrial impairment, and apoptosis
• Nitric oxide (NO) dysregulation: iNOS upregulation produces excessive NO in early sepsis causing vasodilation and hypotension ("distributive shock"), while reduced eNOS impairs endothelial barrier function
• Bradykinin, substance P, and platelet-activating factor (PAF) increase vascular permeability; result is third-spacing—fluid shifts into interstitium despite systemic volume depletion at cellular level

Neutrophil Dysfunction and NET Formation

• Neutrophil extracellular traps (NETs) are web-like structures of decondensed chromatin, histones, and cytoplasmic proteins released through NETosis (programmed cell death distinct from apoptosis)
• NET-associated histones (H1, H2A, H2B, H3, H4) and high-mobility group box 1 (HMGB1) are themselves DAMPs, perpetuating inflammation and directly causing endothelial injury
• Neutrophil priming by TNF-α and IL-1β enhances oxidative burst capacity but also increases tissue damage through elastase and collagenase release
• Neutrophil exhaustion develops with impaired chemotaxis, reduced oxidative burst, and diminished killing capacity—paradoxically occurring despite elevated numbers (left shift with immature band forms)
• CD14+ monocyte-derived microparticles and tissue factor-bearing microparticles amplify thromboinflammation

Metabolic and Mitochondrial Dysfunction

• Mitochondrial damage from ROS, impaired electron transport chain function, and reduced ATP production drives bioenergetic failure
• Lactate accumulation from tissue hypoxia and mitochondrial dysfunction drives metabolic acidosis; elevated lactate-to-pyruvate ratio indicates severe cellular dysfunction
• Aerobic glycolysis paradox: increased glucose utilization without commensurate ATP production, necessitating increased glucose consumption while cellular function declines
• Immune cell metabolic reprogramming: macrophages shift to glycolysis (M1 pro-inflammatory phenotype) while lymphocytes undergo apoptosis due to energy depletion and activation-induced cell death (AICD)

Immunosuppression Phase ("Compensatory Anti-Inflammatory Response Syndrome" - CARS)

• IL-10 and TGF-β surge following initial TNF-α/IL-1β peak, suppressing Th1 response and promoting Th2/Treg differentiation
• PD-1 and PD-L1 upregulation on T cells and antigen-presenting cells drives T cell exhaustion and functional anergy
• Lymphocyte apoptosis occurs through Fas/FasL and TRAIL pathways; CD4+ T cells and B lymphocytes are preferentially lost
• Monocyte deactivation: HLA-DR expression decreases (HLA-DR <30% of monocytes indicates severe immunosuppression), and IL-12 production declines, impairing Th1 differentiation
• Neutrophil immunoparalysis: reduced phagocytosis, impaired cytokine production, and defective apoptosis (extended survival with reduced killing) paradoxically increase infection risk
• Secondary infections with opportunistic pathogens (Candida, Pneumocystis, CMV) emerge 3-5 days into sepsis from this immunosuppressed state

Organ-Specific Pathology

Lungs—Acute Respiratory Distress Syndrome (ARDS)

• Acute exudative phase (days 0-7): increased capillary permeability, protein-rich edema fluid, and hyaline membrane formation (fibrin, cellular debris, and edema fluid lining alveolar spaces)
• Hyaline membranes are hallmark pathological finding—appear as eosinophilic, granular, homogeneous lining along alveolar walls under light microscopy
• Neutrophil infiltration and release of elastase and collagenase damage alveolar epithelium; type I pneumocyte necrosis and sloughing
• Reduced pulmonary surfactant production (type II pneumocyte dysfunction) and increased surfactant inactivation worsen compliance

Kidneys—Acute Kidney Injury (AKI)

• Acute tubular necrosis (ATN) predominates: proximal tubule (S3 segment particularly vulnerable due to high metabolic demand) and thick ascending limb necrosis
• Ischemic ATN from renal hypoperfusion (septic shock) combined with direct endotoxin/cytokine injury
• Acute glomerulonephritis may occur (sepsis-associated GN with immune complex deposition); typically mild proteinuria and hematuria
• Interstitial edema and infiltration by neutrophils and mononuclear cells; myoglobinuria and hemoglobinuria may worsen tubular injury

Liver—Sepsis-Associated Liver Dysfunction

• Hepatocyte necrosis: typically periportal (Zone 2) rather than centrilobular, though bridging necrosis can occur in severe cases
• Hepatic mitochondrial dysfunction impairs synthetic function (reduced albumin, coagulation factors) and detoxification
• Cholestasis: bile plugs in canaliculi, hepatocyte vacuolization, and reduced bile flow from endotoxin effects on contractile elements
• Kupffer cell hyperactivation with lipid-laden macrophages; neutrophil infiltration prominent
• Histologically may show fatty infiltration, ballooning hepatocytes, and minimal inflammation disproportionate to degree of dysfunction

Heart—Sepsis-Induced Cardiomyopathy

• Myocardial dysfunction without coronary artery disease or myocardial infarction; global hypokinesis with reduced ejection fraction
• Myofibrillar damage: disrupted Z-discs, mitochondrial swelling, lipid accumulation
• Cytokine-mediated (TNF-α, IL-1β) and ROS-mediated myocyte apoptosis
• Catecholamine-induced cardiomyopathy from excessive endogenous or exogenous catecholamine exposure

Brain—Sepsis-Associated Encephalopathy

• Cerebral edema from BBB breakdown; minimal inflammation relative to degree of dysfunction (non-inflammatory encephalopathy)
• Microglial activation and astrocytosis; neuronal apoptosis
• ROS and HMGB1-mediated direct neuronal injury
• Cerebral microvascular thrombosis and perfusion deficits

Infectious Causes

Bacterial

• Gram-negative organisms (E. coli, Klebsiella, Pseudomonas aeruginosa, Acinetobacter, Proteus)—LPS production drives potent TLR4 activation; frequently associated with bacteremia and septic shock
• Gram-positive organisms (Staphylococcus aureus including MRSA, Streptococcus pneumoniae, Enterococci)—peptidoglycan and lipoteichoic acid activate TLR2
• Anaerobic organisms (Bacteroides, Clostridium, Peptostreptococcus)—often polymicrobial with gram-negatives; associated with intra-abdominal sources
• Mycobacteria (M. tuberculosis, atypical mycobacteria in immunocompromised hosts)
• Spirochetes (Leptospira, Borrelia burgdorferi—rare)

Fungal

• Candida albicans and non-albicans species (C. auris, C. glabrata, C. tropicalis)—increasingly common with broad-spectrum antibiotics, central lines, and immunosuppression
• Aspergillus fumigatus—primarily in neutropenic and transplant patients
• Cryptococcus neoformans—primarily in HIV/AIDS with CD4 <100
• Pneumocystis jirovecii—primarily in AIDS, presents with ARDS

Viral

• Influenza and coronaviruses (including SARS-CoV-2)—direct viral injury and secondary bacterial superinfection
• Herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV)—disseminated disease in immunocompromised
• Hemorrhagic fever viruses (Ebola, dengue)—systemic vascular leak and coagulopathy

Parasitic

• Plasmodium species (malaria—particularly P. falciparum)—severe malaria with ARDS, cerebral malaria, acute kidney injury
• Schistosoma, Trypanosoma—in endemic regions

Primary Infection Sites

• Respiratory tract (community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia)—most common source, 30-40% of sepsis cases
• Urinary tract and upper genitourinary system (pyelonephritis, prostatitis)—particularly with obstruction or instrumentation; 20-25% of sepsis
• Intra-abdominal sources (perforated viscus, appendicitis, diverticulitis, cholecystitis, spontaneous bacterial peritonitis)—associated with worse prognosis due to polymicrobial infection
• Bloodstream infections (central line-associated bloodstream infections [CLABSIs], endocarditis, bacteremia from other sources)—primary bacteremia in 5-10%
• Skin and soft tissue (necrotizing fasciitis, erysipelas, infected pressure ulcers, surgical site infections)
• Meninges (bacterial meningitis)—fulminant course with high mortality
• Others: endometritis, cholangitis, osteomyelitis, diabetic foot infections

Non-Infectious SIRS Triggers (Sepsis-Mimickers)

• Severe trauma and burns (>15-20% body surface area)
• Acute pancreatitis (leakage of pancreatic enzymes and activation of innate immunity)
• Myocardial infarction and acute coronary syndrome (myocardial necrosis and DAMPs)
• Massive transfusion (incompatibility, contamination, transfusion-related acute lung injury [TRALI])
• Perioperative period (tissue trauma, ischemia-reperfusion injury)
• Reperfusion injury following revascularization or organ transplantation

Cardinal SIRS findings and their mechanisms

• Fever or hypothermia: IL-1β and IL-6 raise the hypothalamic setpoint via PGE2; hypothermia in the elderly, cirrhotic, or uremic patient signals failed thermoregulation and carries a worse prognosis than fever
• Tachycardia with bounding pulses and a wide pulse pressure: iNOS-derived nitric oxide collapses systemic vascular resistance, so cardiac output rises — the warm shock phenotype with flushed, warm extremities and brisk capillary refill
• Tachypnea and early respiratory alkalosis: cytokines directly stimulate the medullary respiratory centers before any hypoxemia develops; a low PaCO2 is often the earliest abnormal vital sign
• Hypotension refractory to fluids: vasoplegia plus glycocalyx degradation and capillary leak (third-spacing) produce both distributive and relative hypovolemic physiology

Organ-dysfunction findings

• Altered mentation, delirium, or simply "not acting right": blood–brain barrier breakdown and microvascular thrombosis in sepsis-associated encephalopathy — frequently the presenting complaint in older adults, who may be afebrile
• Oliguria and rising creatinine: renal hypoperfusion plus direct endotoxin-mediated tubular injury
• Hypoxemia with bilateral crackles and diffuse infiltrates: exudative-phase ARDS from alveolar–capillary leak
• Mottled skin, acrocyanosis, delayed capillary refill, cool extremities: late cold shock, indicating exhausted compensation and sepsis-induced cardiomyopathy
• Petechiae, purpura, oozing from venipuncture sites: consumptive coagulopathy; purpura fulminans with meningococcemia
• Ileus, jaundice, hyperbilirubinemia: splanchnic hypoperfusion and cholestatic hepatic dysfunction

Initial bedside screening

• SIRS criteria (historical but still tested): temperature >38°C or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32 mmHg, WBC >12,000/μL or <4,000/μL or >10% bands — ≥2 defines SIRS; highly sensitive, poorly specific
• qSOFA: respiratory rate ≥22/min, altered mentation, systolic BP ≤100 mmHg — a prognostic flag, not a rule-out. The Surviving Sepsis Campaign explicitly recommends against qSOFA as the sole screening tool, favoring SIRS, NEWS, or MEWS

Laboratory sequence

• Serum lactate: obtain immediately and repeat within a few hours; ≥4 mmol/L mandates aggressive resuscitation. Elevation reflects both hypoperfusion and mitochondrial/adrenergic-driven aerobic glycolysis, so it is not purely an oxygen-debt marker
• Blood cultures ×2 sets from separate sites, drawn before antibiotics — the microbiologic gold standard, but negative in a substantial fraction of true sepsis; do not let culture collection delay therapy beyond a few minutes
• CBC with differential: leukocytosis with left shift and toxic granulation, or ominous leukopenia; thrombocytopenia is an early organ-failure marker
• CMP, bilirubin, ABG: early respiratory alkalosis evolving into anion-gap metabolic acidosis
• Coagulation panel for DIC: prolonged PT/aPTT, falling fibrinogen, markedly elevated D-dimer, schistocytes; scored formally with the ISTH DIC score
• Procalcitonin: adjunct for antibiotic de-escalation, not for making the diagnosis

Immediate stabilization (first hour)

• Measure lactate, obtain blood cultures before antibiotics, then give broad-spectrum IV antimicrobials — administer within 1 hour for septic shock or high-probability sepsis; each hour of delay increases mortality
• Balanced crystalloid (lactated Ringer's, Plasma-Lyte) 30 mL/kg for sepsis-induced hypotension or lactate ≥4 mmol/L; balanced fluids are suggested over large-volume normal saline
• Vasopressors for MAP ≥65 mmHg if hypotension persists during or after fluids — start peripherally rather than delay for central access

Antimicrobial choice

• Anti-MRSA agent: vancomycin, dosed to a 24-hour AUC/MIC of 400–600 per the 2020 IDSA/ASHP consensus (trough-only targeting is obsolete)
• Antipseudomonal beta-lactam: piperacillin-tazobactam, cefepime, or a carbapenem for resistance risk
• Empiric antifungal (echinocandin, e.g., micafungin) for neutropenia, prolonged broad-spectrum exposure, or central lines
• De-escalate by culture and clinical trajectory; procalcitonin can support stopping

Hemodynamic escalation

• Norepinephrine: first-line vasopressor (α1 vasoconstriction restores SVR with less tachyarrhythmia than dopamine)
• Vasopressin: added as the second agent to spare catecholamine dose
• Epinephrine: third-line; dobutamine added for sepsis-induced cardiomyopathy with persistent hypoperfusion
• IV hydrocortisone (200 mg/day, infusion or divided) for shock requiring ongoing significant vasopressor support — addresses critical illness–related corticosteroid insufficiency

Disease-related — emergencies flagged

• ARDS (emergency): alveolar–capillary leak with hyaline membranes; signaled by worsening hypoxemia, PaO2/FiO2 ≤300, and bilateral infiltrates not explained by heart failure (Berlin definition). Requires immediate lung-protective ventilation
• Disseminated intravascular coagulation (emergency): tissue-factor–driven consumption of platelets and factors with PAI-1–mediated fibrinolytic shutdown; signaled by falling platelets and fibrinogen, rising D-dimer, schistocytes, and oozing from puncture sites. Purpura fulminans with protein C depletion causes symmetric peripheral gangrene
• Waterhouse-Friderichsen syndrome (emergency): bilateral adrenal hemorrhage in fulminant meningococcemia, producing refractory shock plus hyponatremia, hyperkalemia, and hypoglycemia
• Acute kidney injury: ischemic ATN with muddy brown granular casts, oliguria, and a rising creatinine; may progress to dialysis dependence
• Sepsis-induced cardiomyopathy: cytokine- and ROS-mediated global hypokinesis with a depressed ejection fraction that typically reverses within days to weeks
• Shock liver and cholestasis: transaminases in the thousands after a hypotensive episode; conjugated hyperbilirubinemia
• Secondary/opportunistic infection: CARS-phase immunoparalysis (low monocyte HLA-DR, lymphopenia) permits Candida, CMV reactivation, and hospital-acquired pneumonia days into the illness
• ICU-acquired weakness and post-intensive care syndrome: critical illness polyneuromyopathy plus long-term cognitive and functional impairment

Treatment-related

• Vasopressor complications: digital, mesenteric, and skin necrosis from intense α1 vasoconstriction; extravasation injury from peripheral infusion (treated with phentolamine)
• Fluid overload: pulmonary edema, worsening oxygenation, and abdominal compartment syndrome after high-volume resuscitation — de-resuscitate once perfusion is restored
• Hyperchloremic non–anion-gap metabolic acidosis from large-volume normal saline
• Nephrotoxicity: vancomycin, amplified when combined with piperacillin-tazobactam; monitor with AUC-guided dosing
• ***Clostridioides difficile* colitis** from broad-spectrum exposure
• Ventilator-associated pneumonia and barotrauma/pneumothorax from mechanical ventilation
• Hyperglycemia from stress response and steroids, requiring insulin with avoidance of tight-control hypoglycemia

• Warm shock is the signature hemodynamic profile: low systemic vascular resistance, high cardiac output, high mixed venous oxygen saturation (impaired mitochondrial extraction), warm extremities, and a wide pulse pressure. Cardiogenic and hypovolemic shock are the mirror image — high SVR, low CO, low SvO2, cold clammy skin. This single table of physiology is the most commonly tested discriminator.
• Single best next step in a hypotensive febrile patient: draw blood cultures, then give broad-spectrum antibiotics and 30 mL/kg balanced crystalloid within the first hour (Surviving Sepsis Campaign 2021). Antibiotics are never delayed for imaging or lumbar puncture in shock.
• Sepsis-3 replaced the SIRS-based definition: sepsis = infection + SOFA rise ≥2; septic shock = vasopressors needed for MAP ≥65 plus lactate >2 mmol/L after adequate fluids. "Severe sepsis" is a retired term.
• Norepinephrine is first-line, not dopamine — dopamine causes more tachyarrhythmias. Vasopressin is the add-on; hydrocortisone is for shock with ongoing vasopressor requirement.
• Source control determines survival: an abscess, infected line, obstructed ureter, or necrotizing soft-tissue infection must be drained, removed, or debrided. A stem with persistent fever despite appropriate antibiotics is asking about undrained source, not antibiotic resistance.
• DIC classic triad: thrombocytopenia + prolonged PT/aPTT + low fibrinogen with markedly elevated D-dimer. Fibrinogen is the discriminator from other consumptive states; treat the underlying sepsis and transfuse only for bleeding or planned procedures.
• Meningococcemia with refractory shock and hypoglycemia = Waterhouse-Friderichsen (bilateral adrenal hemorrhage) — a classic association examiners return to.
• Common distractors: qSOFA is not endorsed as a stand-alone screening tool; procalcitonin does not diagnose sepsis (it guides de-escalation); hydroxyethyl starch and activated protein C are not used; and an elevated lactate in sepsis is not purely anaerobic — it also reflects catecholamine-driven aerobic glycolysis.